Previous close | 40.48 |
Open | 0.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 0.00 - 0.00 |
52-week range | |
Volume | |
Avg. volume | 4,975 |
Market cap | 48.017M |
Beta (5Y monthly) | 1.45 |
PE ratio (TTM) | 0.08 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Lazard's (LAZ) AUM balance in February benefits from a positive market, offset by net outflows and foreign exchange depreciation.
Moody's (MCO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Spanish pharmaceutical company Rovi said on Thursday it had hired financial advisory and asset management firm Lazard to explore the sale of its third-party manufacturing business that it uses to make COVID vaccines. Madrid-based Rovi said it regularly assesses potential strategic alternatives to maximise value and decided to hire Lazard, although no specific decision had been taken and the analysis was still ongoing.